Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
3 pending office actions • 3 art units • 2 examiners • 0 of 3 (0%) have an AI response strategy ready
Accuragen Holdings Limited is managing 3 pending office actions in the Biotechnology & Pharmaceuticals technology area. These actions are distributed across 2 distinct examiners, showing that the company is navigating multiple review processes within the patent office. This distribution indicates that the company's biotechnology interests are sufficiently diverse to require attention from more than one technical expert. Practitioners should be prepared to manage multiple examiner timelines within this sector.
Allison Elizabeth Schloop is the busiest examiner, overseeing 2 busiest examiner pending actions. The portfolio's active matters are spread across 3 distinct art units. This means that while the 3 pending office actions are spread across 3 distinct art units, one examiner handles the majority of the active workload. This concentration with Allison Elizabeth Schloop suggests a primary point of contact for the company's current biotechnology prosecution. Practitioners should be aware that the outcomes in the 2 cases handled by Allison Elizabeth Schloop will significantly impact the overall health of the pending portfolio. The involvement of 3 distinct art units indicates a relatively broad technical scope.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 2 (67%) |
| Double-patenting + other | 1 (33%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| SCHLOOP, ALLISON ELIZABETH | 2 | 63.0% | +56.5% |
| FLINDERS, JEREMY C | 1 | 63.5% | +16.7% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18054676 | CELL-FREE DNA SIZE DETECTION | SCHLOOP, ALLISON ELIZABETH | 9d |
| 18315025 | METHODS AND SYSTEMS FOR SAMPLE NORMALIZATION | SCHLOOP, ALLISON ELIZABETH | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18054676 | CELL-FREE DNA SIZE DETECTION | SCHLOOP, ALLISON ELIZABETH | 9d |
| 18315025 | METHODS AND SYSTEMS FOR SAMPLE NORMALIZATION | SCHLOOP, ALLISON ELIZABETH | — |
| 18191792 | COMPOSITIONS AND METHODS FOR DETECTING RARE SEQUENCE VARIANTS | FLINDERS, JEREMY C | — |
| Art Unit | Apps |
|---|---|
| 1682 | 1 |
| 1684 | 1 |
| 1683 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18315025 | METHODS AND SYSTEMS FOR SAMPLE NORMALIZATION | SCHLOOP, ALLISON ELIZABETH | 1682 | §101§112 | Non-Final OA | — | Pending | May 10, 2023 |
| 18191792 | COMPOSITIONS AND METHODS FOR DETECTING RARE SEQUENCE VARIANTS | FLINDERS, JEREMY C | 1684 | §102§103DP | Non-Final OA | — | Pending | Mar 28, 2023 |
| 18054676 | CELL-FREE DNA SIZE DETECTION | SCHLOOP, ALLISON ELIZABETH | 1683 | §101§103§112 | Final Rejection | 9d | Pending | Nov 11, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial